Screener
Insight Molecular Diagnostics Inc. IMDX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Insight Molecular Diagnostics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Insight Molecular Diagnostics Inc.’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001642380-26-000011
FAQ
- What is Insight Molecular Diagnostics Inc.'s EPS (diluted)?
- Insight Molecular Diagnostics Inc. (IMDX) reported EPS (diluted) of -$0.31 in Q2 2026.
- How has Insight Molecular Diagnostics Inc.'s EPS (diluted) changed year-over-year?
- Insight Molecular Diagnostics Inc.'s EPS (diluted) decreased by 3.3% year-over-year, from -$0.30 to -$0.31.
- What is the long-term trend for Insight Molecular Diagnostics Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Insight Molecular Diagnostics Inc.'s EPS (diluted) has grown at a 36.0% compound annual growth rate (CAGR), from -$0.48 to -$1.64.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Insight Molecular Diagnostics Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude